Open AccessAnticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
Author(s) -
Takashi Matsumoto,
Masaki Shiota,
Shuhei Yamada,
Leandro Blas,
Hidekazu Naganuma,
Ken Lee,
Keisuke Monji,
Eiji Kashiwagi,
Ario Takeuchi,
Junichi Inokuchi,
Kenichiro Shiga,
Akira Yokomizo,
Masatoshi Eto
Publication year - 2022
Publication title -
jma journal
Language(s) - English
Resource type - Journals
eISSN - 2433-3298
pISSN - 2433-328X
DOI - 10.31662/jmaj.2021-0163
Subject(s) - docetaxel , medicine , prostate cancer , hazard ratio , oncology , androgen receptor , second line treatment , prostate specific antigen , subgroup analysis , confidence interval , abiraterone acetate , androgen deprivation therapy , cancer , urology , overall survival
Studies on the effect of androgen receptor pathway inhibitors (ARPI), docetaxel (DTX), and radium-223 (Ra-223) after first-line treatment with ARPI in patients with castration-resistant prostate cancer (CRPC) are scarce. This study compared the efficacy of treatment after ARPI for CRPC.